Navigation Links
MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
Date:2/23/2009

MOUNTAIN VIEW, Calif., Feb. 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today results of its initial Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma. The Company announced that the clinical trial did not meet its co-primary endpoints, asthma control as assessed by changes from baseline in nighttime and daytime composite symptom scores, in either of the doses evaluated, when compared with placebo. Median nebulization times were less than four minutes for both doses in the study. Initial review of the data has not identified any serious adverse events attributed to study drug. Patients continue to be treated in a 52-week safety study to collect long-term safety data on the two doses under investigation.

"Based on our initial review of these data, both the placebo and study groups experienced improvements in asthma symptoms, but the differences were not statistically significant. We observed a higher than expected response in the placebo group, starting as early as one week after randomization and continuing throughout the 12 week treatment period," said Timothy S. Nelson, Chief Executive Officer of MAP Pharmaceuticals. "We and our partner, AstraZeneca, are conducting further analyses of these data to determine appropriate next steps going forward for the program. The Company remains dedicated to developing therapies for children suffering from asthma."

About the AstraZeneca Collaboration

MAP Pharmaceuticals and AstraZeneca have a collaboration agreement to develop and commercialize UDB in the United States, and AstraZeneca has rights to develop and commercialize UDB outside of the United States.

About the Study

In this randomized, double-blind, placebo-controlled study, 360
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
2. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
3. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
4. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
5. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
6. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
7. Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
8. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
9. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
10. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
11. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...a/--ChindexInternational,Inc.,("Chindex")(Nasdaq: ...n,healthcareproductsandservicesinthePeople,sRepubl...he21stAnnualPiperJaffray,"Unplugged"HealthCareConf...eHotel. , Managementiscurrentlyscheduledtopre...e-on-onemeetingsthroughouttheday.Awebcast,ofthepre...
(Date:11/24/2009)...ll/--AnadysPharmaceuticals,Inc.(Nasdaq: ANDS )anno...frayHealthcareConferenceonTuesday,December1,2009at...tTheNewYorkPalaceHotel.SteveWorland,Ph.D.,Presiden...rviewofAnadysanditsclinicaldevelopmentprograms,ANA...simultaneouslywebcastandcanbeaccessedontheInvestor...
(Date:11/24/2009)...-ZargisMedicalCorp.,asubsidiaryofSpeedusCorp.(Nasd...(NYSE: SI ),todayannouncedthatitsZargisCardioscand...TheEarlyShow duringasegmentinwhichMarkJannot,theed...productsfromthepublication,s2009"BestofWhat,sNew"a...ionmorningnewstalkshowbroadcastbyCBSfromNewYorkCit...
Breaking Medicine Technology:Chindex International to Present at Piper Jaffray Health Care Conference 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 3Cystic Fibrosis Treatment May Cause Hearing Loss 50673 1Cardinal Health Appoints Bruce Downey to Board of Directors 3B John McCoy Retires From Board After 22 Years 50670 1Cardinal Health Appoints Bruce Downey to Board of Directors 3B John McCoy Retires From Board After 22 Years 50670 2CyberGlove Systems Hosts Worldwide Contest for New Motion Capture Technology Applications 50667 1CyberGlove Systems Hosts Worldwide Contest for New Motion Capture Technology Applications 50667 2CyberGlove Systems Hosts Worldwide Contest for New Motion Capture Technology Applications 50667 3
...mmary: Proprietary DNA delivery technology enables...cells - reduces,atherosclerosis progression in mou...WIRE)--Mar 26, 2007 - Research conducted,at Clevel...lege of,Cardiology,s 58th Annual Scientific Sessio...ing the anti-inflammatory protein,interferon-beta ...
...ISIS 301012 coadministered with statins for only f...the levels achieved with,statins alone, with simil..., NEW ORLEANS and CARLSBAD, Calif., March 26, 2007...nc. announced new,results from its Phase 2 clinica... presented today at the of Cardiology,Annual Scien...
Other Medicine Technology:Interferon Beta DNA Treatment Delivered with Ichor Technology,Reduces Atherosclerosis Progression in Mice 2Interferon Beta DNA Treatment Delivered with Ichor Technology,Reduces Atherosclerosis Progression in Mice 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 2Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 4Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 6Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 7Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 8Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 9
(Date:11/25/2009)...swire-USNewswire/--TheAmericanAssociationforHomeca...S.2128,whichisdesignedtosubstantiallyimprovetoolsa...llwasintroducedbySen.GeorgeLeMieux(R-Fla.). ,, ...AssociationforHomecareoutlinedinits13-pointanti-fr...sinFebruary.Thoseprovisionsincludecallingforreal-t...
(Date:11/25/2009)...at can occur in children with autism and related c...t includes medication combined with a structured t...versity researchers and their colleagues. , Pub...of the American Academy of Child and Adolescent Ps... Institute of Mental Health (NIMH) Research Units ...
(Date:11/25/2009)...ve expands to include cost-effective, sustainable ...thcare professionals in developing world. , ... 25, 2009 -- Elluminate, Inc. , the leader in we...hat support 21st century teaching, learning, and c...ce initiative was awarded iNACOL,s first-ever Ou...
(Date:11/25/2009)...Newswire/--TwomoreH1N1vaccineclinicshavebeenschedu...ntyHealthDepartmentannouncedtoday.Theyarebeingoffe...rkinSterlingHeights. ,, TheDec.3clinicwillbehel....Thethimerosol-freeversionoftheinjectablevaccinewi...ectableandnasalsprayimmunizationwillbeoffered.Preg...
(Date:11/25/2009)...gresstoImproveOverallOutcomesforLungCancer ,,...,LungCancerAlliance-California(LCA-CA)issuedits2nd...anassessmentofprogressbeingmadeagainstthislethaldi...CancerAlliance(LCA),theonlynationalorganizationded...plelivingwithoratriskforlungcancer. ,, (Photo: ...
Breaking Medicine News(10 mins):Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2Health News:Parent training key to improved treatment of behavior problems in children with autism 2Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 2Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 3Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 4Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 5Health News:Macomb County Health Department Schedules Two More H1N1 Flu Vaccine Clinics Dec. 3 and 5 2Health News:Lung Cancer Alliance-California Releases 2nd Annual State-Specific Report Card On Lung Cancer 2
...ld Allow Condom Distribution in CA Correctional,Fa...lifornia HIV Advocacy Coalition (SCHAC) and the Ca... on Tuesday, October 2, at 10:00 a.m. (in front,of...y Act" (Swanson, D, Oakland), which will help redu...
...stored normal blood pressure, study finds , ...n study has identified overweight as a direct caus...up to half of overweight people can bring down blo... Dr. Roberto Fogari, professor of medicine at the ...
...to warn Americans about risks of indoor tanning de...rtant step,which may help reduce significantly the...Bush yesterday signed the Tanning Accountability a... directs the U.S. Food and Drug Administration (FD...
...as An inflammatory eye condition that is one of t...ated much more effectively and easily thanks to a ...ory rats, scientists at the University of Texas Me... outer surface of the eyeball and includes the iri...
... be Cut; Plan Changes Will Reduce Cost Increases b... HARRISBURG, Pa., Sept. 28 The Office of,Administ... Retired,Employees Health Program (REHP) that will...challenges facing,employers across the country," S...
...2007 (Aliso Viejo, CA) Ossur, a trusted and globa...etic innovations than any other company in the fie...s the winner of a 2007 da Vinci Award. , The PR...lectronics, mechanics, and human physiology that r...
Other Medicine News:Health News:Community Leaders to Host Press Event at L.A. Central Jail Urging Governor to Sign AB 1334 2Health News:Weight Loss Can Control Hypertension 2Health News:Weight Loss Can Control Hypertension 3Health News:American Academy of Dermatology Association Commends President Bush for Signing Tanning Accountability and Notification (TAN) Act 2Health News:New discovery may improve treatment of one of the world's leading causes of blindness 2Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 2Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 3Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 4Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 5Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 6Health News:Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees 7Health News:Ossur's Proprio Foot nets the 2007 da Vinci Award 2
Full Handle Laseredge Implant Blade Knife, 3.2 mm round tip
Full Handle Laseredge Implant Blade Knife, 5.2 mm angled bevel up
Full Handle Laseredge Implant Blade Knife, 4.0 mm angled bevel up
Full Handle Laseredge Crescent Blade Knife, angled bevel down
Medicine Products: